Day 1 :
Keynote Forum
Abdulaziz Saddique
Qimat Tayba Pharmaceutical Biotechnology Factory, Saudi Arabia
Keynote: Pharmaceutical biotechnology manufacturing the future of medicine
Time : 09:20-09:50
Biography:
Abdulaziz A Saddique has a Bachelor of Pharmacy Degree from King Saud University and Doctorate degree in Clinical Pharmacy from the University of Minnesota. He is a Certified Clinical Toxicologist and Clinical Pharmacy Specialist in Intensive Care, also is a Certified Professional in Health Care Quality (CPHQ), California, USA and Certified Six Sigma Master Black Belt. He is a member of King Abdulaziz Quality Award, Committee, and Healthcare Standards Committee Ministry of Health. He published seven books on Quality Management, Pharmacy, and Toxicology and more than 100 papers in national and international journals.
Abstract:
Pharmaceutical Biotechnology is an increasingly significant field of science and engineering, it revolutionizes the ways by which diseases are diagnosed, treated, and foreclosed. Biopharmaceutics contributes to the design and delivery of new therapeutic drugs, development of diagnostic agents for medical examinations and developing Monoclonal Antibody for Cancer therapy. The societal implications of Pharmaceutical Biotechnology are similarly widespread, ranging from many ethical issues of identifying and treating various hereditary diseases, to changes in healthcare practices and a significant contribution to national economic development. In Saudi Arabia 30% of the population are diabetics, 5% are Hemophiliac, 7% have Thalassemia major and 5-7% have an end stage kidney disease and are on dialysis. This shows the expanding market of Biotechnology products need. Due to the difference in genomes and the potential risk involved with the preparation, administration and the consequences of vaccinations, it is essential to develop the necessary vaccines within every country. It is an essential component of the National Security to have our own biotechnology, studying our own genomes and developing all the necessary vaccines, medications and hormones in accordance to our own genetic code. This paper will outline the potential risk of some vaccines, the impact on the individuals and communities. It will demonstrate the value of having R&D and not just being a copier of what other nations have created and engineered. Also we will discuss our own biotechnology plan for the near future as well as the long term.
Keynote Forum
Andrzej Pilc
PAS-Institute of Pharmacology, Poland
Keynote: The antipsychotic activity of mGlu receptor agents, focus on novel allosteric vs. orthosteric agonists of mGlu4 receptors
Time : 09:50-10:20
Biography:
Andrzej Pilc, MD, PhD is now the Head of Neurobiology Department at the Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. His main research interest is in the studies of the mechanism of action of antidepressant/anxiolytic/antipsychotic drugs including the involvement of mGlu or GABAB receptor ligands. He is a principal investigator in a number of grants, received several national awards and is one of the most frequently cited Polish pharmacologists.
Abstract:
Modulation of the glutamatergic system via metabotropic glutamate receptors (mGlu) including mGlu5 receptor, positive allosteric modulators (PAMs) and mGlu2/3 receptor stimulators which could be a new, efficient way to achieve antipsychotic-like effects. The metabotropic glutamate 4 (mGlu4) receptor is the most studied among group III mGlu receptors. The antipsychotic activity of the non-selective orthosteric agonist of mGlu4/mGlu8 receptors, ACPT-I was demonstrated. The activity of the compound was evident in the models’ predictive of positive symptoms, moreover, it was shown that ACPT-I dose-dependently inhibited spontaneous EPSC evoked by DOI administration in rat frontal cortex. Similar results were obtained for the second orthosteric agonist of mGlu receptors, LSP1-2111. Later on it was shown that the compound also possessed activity towards negative and cognitive symptoms of schizophrenia, measured in the social interaction and novel object recognition tests. Similar results were obtained with selective mGlu4 receptor PAMs Lu AF21934 or ADX88178. These compounds showed an antipsychotic-like activity in animal models, albeit the efficacy of the former compound was stronger than that for the latter one. The actions of Lu AF21934 were robust and evident in animal models of positive, negative and cognitive symptoms. The administration of the selective 5-HT1A antagonist WAY100635 fully reversed the action of both LSP1-2111 (orthosteric agonist) and Lu AF21934 (positive allosteric modulator) in preclinical models considered as mirroring positive, negative and cognitive symptoms of schizophrenia. Simultaneously, the administration of sub-effective doses of the ligands induced clear antipsychotic-like effects not observed for each compounds separately. Therefore it can be speculated that the combined treatment based on the mGlu4-5-HT1A agonism may be regarded as a potentially effective new antipsychotic treatment.
- Market surveillance of industrial pharmacy, Industrial Pharmacy Management, Drug Design and Marketing, Drug Development Stages
Session Introduction
Yousef Alomi
Ministry of Health, Saudi Arabia
Title: Pharmaceutical care strategic plan with pharmaceutical companies; future vision in Saudi Arabia
Time : 11:10-11:35
Biography:
Yousef Alomi completed his studies from King Saud University with the degree of Bachelor of Pharmaceutical Sciences in the year 1992. After six-years of higher studies, he earned his Master of Clinical Pharmacy from the same University in 1998. He is an affiliated clinical instructor of Purdue University in the USA. He is adjunct Assistant Professor of King Saud University College of Pharmacy. He was a member of Pharmacy Board at Saudi Commission for Health Specialties for 1998-2002 and 2008-2012 and Head of Pharmacy Accreditation Committee in 2010-2012. He was team member of establishing 1st Pharmacy Residency Program in Saudi Arabia. In the year 2005, he obtained Board Certification of Pharmacotherapy Specialist (BCPS). He became a member of advisory board of the Arab Pharmaceutical Journal in 2010. He was Pharmacy Board Member of Saudi Commission of Health Care Specialities from 2010-2013. He had several researches in clinical Pharmacy and pharmacy practice published in ACCP and ISPOR conferences. He had several presentations in clinical pharmacy and pharmacy practice at several conferences in and outside Saudi Arabia.
Abstract:
Strategic plan of GAPC towards pharmaceutical companies was found to establish collaboration between them. There is some misuse or non-organized distribution of educational resources with unclear vision. Strategic plan of pharmaceutical care consulting of several fundamental elements, and they are not limited to Medication Safety Program including Medication errors, Adverse drug reaction, drug quality reporting system, and RIMP system. Clinical Pharmacy programs including anticoagulation program, pain management program, and pharmacy diabetes care program, etc. Pharmacy Practice program including stability of intravenous medications, pharmacy human resources with training and education, residency programs, and pharmaceutical care local or international conferences. Pharmacy research and development is another vital area for collaboration. The pharmaceutical companies need clear vision and policy with long term partnership. Pharmaceutical care and manufactures gathering may play vital role in building excellent pharmacy career pathway with targeting patient care to reach optimal drug therapy management and prevent drug related misadventures with avoiding un-necessary cost.
Mihir Raval
Saurashtra University, India
Title: Functionality Improvement of APIs: An Important Aspect in Tablet Manufacturing for Oral Targeting
Time : 11:35-12:00
Biography:
Mihir Raval is Head of Department of Pharmaceutical Sciences of Saurashtra University (Accredited Grade “A” by NAAC) at Rajkot, in the state of Gujarat (India). Apart from Pharmacy, he is heading Department of Biochemistry of the same university. He is a Dean of Pharmacy Faculty and a Senate member of the University. He is also serving as Director of Industry Institute Interaction Cell (IIIC) of the Saurashtra University. He has served as a resource person in many national level conferences. He has more than 40 publications in various reputed national and international journals to his credit. He has also worked as Production scientist in Pharma industry.
Abstract:
Most APIs are crystalline solids at room temperature and are commonly delivered as a solid oral dosage forms. The efficacy of the drug is often dependent on the physical properties of the dosage form, and it is well established that the different solid forms of the same compound have different physical and chemical properties. Flow and compatibility of particles or powder are the most important consideration in the solid dosage manufacture. Blending, transfer, storage feeding, compaction, and fluidization, all depends on good powder flow property. The properties include particle size, particle distribution, particle shape, specific surface area, true density, tensile strength, melting form, and polymorphic form. From these fundamental properties arises the other property such as solubility, dissolution rate, flowability, and compactibility. Particle engineering/design techniques are widely used in pharmaceutical industries to modify properties of pharmaceuticals. Especially, improvement in the efficiency of the manufacturing process and high degree of particle functionality can be achieved by these techniques. Improvement in the extent and rate of dissolution of poorly soluble drugs is highly desirable which can lead to an increased and more reproducible oral bioavailability and subsequently to clinically relevant dose reduction and more reliable therapy.
Subrata Ganguli
Calcutta Institute of Pharmaceutical Technology, India
Title: A review on structure-function relationship in protein degradation and its importance in pathology
Time : 12:00-12:25
Biography:
Subrata Ganguli had completed his Ph.D. from the University of Illinois at Chicago, USA after completing his education in the Indian Insitutes of Technologies. He was a recepient of the prestigious JBNSTS Undergraduate Fellowship. He had been active in theIndian Academy press and the internet media authoring on several scientific and publc issues. He has presented more than 10 papers.
Abstract:
Structure-function relationship is a key to the understanding of functioning of bioactive molecules, as well as a prerequisite for predictive analysis and design of novel molecules with desirable bioactive properties. The authors group had analysed various in silico methodologies ( Ganguli and Sharma, Computer Society of India Communication, January 2016, pp 26—28) and the use of open source software packages. Use of open source software and databases permit molecular modeling and predictive design of molecules and of the active site in the protein by homolgy. Stability of a protein molecule in vivo determines the effectiveness of its function under physilogical conditions. Pathological conditions can be traced to malfunctioning of the proteins due the alteration in primary structure by mutation or by alteration in the post-translational modifications affecting functioning of the molecule. This review catalogues few of the better studied protein structures and describe their characteristic peculiarities with the hope that one would be able to develop predictive heuristics.
Manish Sharma
Bahra University, India
Title: Newer α-acyl β-phenylpropanoic acid derivative as PPAR-α based hypolipidemic agent
Time : 12:25-12:50
Biography:
Manish Sharma completed his BPharm from Rajasthan University and Post-graduation from BITS-Pilani. He conducted his Pre-doctoral research from University of Montana and PhD from JNU, Rajasthan. He is Dean of School of Pharmaceutical Sciences, Bahra University, Solan-HP, India. He has published more than 10 papers in reputed journals and has been serving as reviewer of repute. His area of research interest is QSAR and molecular modeling studies of biologically active small molecules.
Abstract:
A comparative QSAR study through Hansch analysis on PPAR α and γ agonists was carried out on following three series: 1) 2-Alkoxydihydrocinnamates. -logEC50=2.053(±0.899)R1Vw-1.921(±0.625)R2Vw+6.476(±0.375) n=12, r=0.95, s=0.18, F=41.37, R2=0.90, R2adj=0.88, RMSE=0.38, Q2=0.81 2) Azaindole-α-alkyloxyphenylpropionic acids. -logEC50= -0.96(±0.472)RVw+0.847(±0.344)I1+0.495(±0.249)I2+6.476 n=18, r=0.94, s=0.19, F=32.58, R2=0.88, R2adj=0.85, RMSE=0.20, Q2=0.78 3) Oxime ethers of α-acyl-β-phenylpropanoic acids. -logEC50=11.344(±6.549)CMR-0.415(±0.255)CMR2-68.072(±42.133) n=15, r=0.90, s=0.26, F=24.84, R2=0.82, R2adj=0.80,RMSE=0.41, Q2=0.73 On the basis of internally and laterally validated QSAR models and results of QSAR equation on oxime ethers of α-acyl-β-phenylpropanoic acids, scaled calculated optimum molar refractivity (CMRo) value of 14.3 for molecules was required for maximum agonistic activity. Using this clue, some oxime ethers of α-acyl-β-phenylpropanoic acids were proposed which were within the probability density derived applicability domain. The structural effects of ligand binding were examined on the basis of hydrogen bond interactions and binding energies in the final complexes obtained from molecular docking simulations. Compound RM-KT-01 was found to possess optimum calculated activity, passed Lipinski’s “rule of five” for oral absorption and lacked toxicity (mutagenicity, carcinogenicity, teratogenicity and embryotoxicity predicted by PASS). The derivative was synthesized and characterized by their physicochemical data and spectral analysis (F.T.I.R, 1H N.M.R., Elemental analysis and Mass spectroscopy). The synthesized compound RM-KT-01 (1) was screened for human PPAR (hPPAR) α agonistic activity on full length PPARα receptor transfected in HepG2 cells. The in vitro PPAR α agonistic activity (EC50) of synthesized compound was reported to be 78 nM. The in vitro activity suggests relevancy of presence of phenyl carboxamide group at one end and n-butyl group attached with phenylpropanoic acid chain of oxime ether of α-acyl-β phenylpropanoic acid. The result of transactivation assay also suggests that RM-KT-01 (1) is PPAR α selective and shows no activity on PPAR γ and PPAR δ.
Yousef Alomi
Head of national drug information centre, MOH Saudi Arabia
Title: Pharmaceutical care strategic plan with pharmaceutical companies future vision in Saudi Arabia
Biography:
Dr. Alomi is a product of King Saud University confirmed with the degree of Bachelor of Pharmaceutical Sciences in the year 1992. After six-years of higher study, he earned his Master of Clinical Pharmacy from the same university in the 1998. He is an affiliated clinical instructor of Purdue University in the USA. He is adjunct assistant professor of King Saud University college of Pharmacy. Dr. Alomi was a member of Pharmacy Board at Saudi commission for health Specialties for 1998-2002 and 2008-2012 and Head of Pharmacy Accreditation committee in 2010-2012. He was team member of establishing 1st Pharmacy Residency Program in Saudi Arabia. In the year 2005 he obtained Board Certification of Pharmacotherapy Specialist (BCPS). In the year 2008, he obtained his diploma in business administration from American University in Egypt in 2007, and he obtained a Board Certification of Nutrition Support Pharmacy (BCNSP) in 2009. Dr. Alomi worked as clinical pharmacist in critical care area and nutrition support. He is He is establish and implement several programs at MOH Hospitals at first time; Clinical Pharmacy Program, Medication Safety Program, Pain Management Program, Anticoagulation Program and Pharmacy Infection Control, including 30 Adult and 20 Paediatrics Clinical Pharmacy Program; he founder of Mass Gathering Pharmaceutical Care in Saudi Arabia. He became a member of advisory board of the Arab Pharmaceutical Journal in 2010. He became as Pharmacy Board Member of Saudi Commission of Health Care Specialities2010-2013. He had several researches in clinical Pharmacy and Pharmacy practice published in ACCP and ISPOR conferences; He had several presentations in the clinical pharmacy and pharmacy practice at several conferences in and outside Saudi Arabia
Abstract:
Strategic plan of GAPC towards pharmaceutical companies was found to establish collaboration between them. There is some misuse or non-organized distribution of educational resources with unclear vision. Strategic plan of pharmaceutical care consulting of several fundamental elements, and they are not limited to Medication Safety Program including Medication errors, Adverse drug reaction, drug quality reporting system, and RIMP system. Clinical Pharmacy programs including anticoagulation program, pain management program, and pharmacy diabetes care program, etc. Pharmacy Practice program including stability of intravenous medications, pharmacy human resources with training and education, residency programs, and pharmaceutical care local or international conferences. Pharmacy research and development is another vital area for collaboration. The pharmaceutical companies need clear vision and policy with long term partnership. Pharmaceutical care and manufactures gathering may play vital role in building excellent pharmacy career pathway with targeting patient care to reach optimal drug therapy management and prevent drug related misadventures with avoiding un-necessary cost.
Raed Al Swayed
Avalon Pharma, Saudi Arabia
Title: Market access methodology in emerging markets – Strategies for pharmaceutical industry market
Biography:
Raed Al Swayed has completed his Pharmaceutical degree in 1995 from King Saud University and Post-doctoral studies from Oxford Management Centre. He is the Managing Director of the Scientific Office/Regulatory & Public Affairs for Avalon Pharma, a premier Pharmaceutical Manufacturer organization in Saudi Arabia. He has 20 years of experience in multi-national & local pharmaceutical industry.
Abstract:
Market Access is a new concept in pharmaceutical industry; pharmaceutical companies need to better incorporate payer perspectives in drug development and commercial decision making. Increasingly strict payer evidence requirements and intense competition mean companies must develop and articulate stronger payer value propositions & manage challenges such as Address payer needs in clinical development programs for new and existing drugs Identify, formulate and test value propositions that government payers and private managed care find compelling. Determine optimal price through interconnected willingness to pay/prescribe studies with payers, physicians and patients’ affordability programs. Test global and design local pricing and reimbursement strategies that maximize return on investment. Improve team’s understanding of the complex payer and market access environment and what it takes to be successful in strategy and implementation. Highlighting Market access concept in Emerging Markets & differentiate the strategies among these markets compared to Global markets, utilizing key success factors, commercial market channels differentiations, market KAM concept type & regulatory deference's in applying Market Access, pricing & commercial operations.
Mahmoud F. Elsebai
Mansoura University, Egypt
Title: Potent and Broad Spectrum Medicinal Drugs against all Genotypes of Hepatitis C Virus (HCV)
Biography:
Mahmoud F. Elsebai is the professor at Mansoura University, Egypt
Abstract:
As many as 200 million people worldwide are infected with hepatitis C virus (HCV). About 3–4 million people are infected per year, and more than 350,000 people die yearly from hepatitis C-related diseases (Menzel et al. 2012), (WHO, June 2011). The Egyptian community is suffering from the prevalence of HCV infections (El-Fakharany et al. 2013). Even in the advanced countries hepatitis C is common and there is no any exclusive cure for hepatitis C either naturally or synthetically. HCV is the most common chronic blood-borne infection and it is the most frequent indication for liver transplantation (Haid et al. 2012). In the United States, hepatitis C is the most common chronic blood-borne infection (http://www.cdc.gov/hepatitis/HCV/ index.htm). The infection with HCV is often asymptomatic but chronic infection leads to liver cirrhosis which usually develops into liver failure, liver cancer or life-threatening esophageal and gastric varices. The diseased-liver person usually undergoes subsequent psychological disorders due to the stress of disease which complicates the illness (Takebe et al. 2013). There is no preventive vaccine available for HCV due to its highly mutable nature evidenced by the presence of more than 50 subtypes of HCV; in addition HCV infects only humans and chimpanzees (Houghton 2009). Fortunately, Dorner et al (Dorner et al. 2013) recently, were able to complete the entire HCV life cycle in genetically humanized transgenic mice with stably expressing human CD81 and OCLN and blunting the antiviral immunity in this mice infected with HCV. The standard therapy pegylated interferon plus ribavirin is only effective in 50–60% of patients and is associated with serious side-effects, and half of those which respond relapse after cessation of interferon treatment. HCV treatment(s) have changed dramatically in the era of Direct-Acting Antivirals (DAAs). Currently approved DAAs include NS3/4A protease inhibitors (telaprevir, boceprevir and simeprevir), NS5A inhibitors (daclatasvir and ledipasvir) and the NS5B polymerase inhibitor sofosbuvir. Although these drugs are showing significantly improved efficacy, treatment with these compounds showed rapid emergence of drug resistant mutants are likely to occur and spread between individuals, highly expensive, and narrow spectral activity towards different genotypes of HCV (Berger et al. 2014; Miura et al. 2014; Farnik & Zeuzem 2012). Therefore, therapeutic alternatives are of major importance and hence there is a continued interest in developing further antiviral drugs with altered mechanisms of action and low production costs. In the present study, through joint work with Spanish and Finnish teams, the water extract of the leaves of the wild Egyptian artichoke (WEA) (Cynara cardunculus L. var. sylvestris (Lam.) Fiori) showed improvement of HCV infection symptoms. Therefore, our study was divided into two main strategies: 1) The clinical investigation of WEA extract on some HCV-infected Egyptian patients (approved by the Ethical Committee of Research at the Faculty of Pharmacy, Mansoura University, Egypt, code number 2014/71). The results showed outstanding activity against HCV and its complications such as ascites and jaundice by measuring the PCR, and liver functions such as ALT, AST. 2) The phytochemistry of the WEA extract and its subsequent evaluation of inhibition capacity in vitro using cell-culture derived HCV: The chemical investigation of the WEA extract resulted in the identification of six compounds: a new sesquiterpene lactone (1), in addition to the known compounds (2-6). Their structural elucidation was done by extensive spectroscopic tools such as NMR and HR-MS spectroscopy. The absolute configuration was determined by TDDFT ECD calculations and comparison with the experimental CD spectra. Compounds 1 and 2 were the most potent among the six by using a luciferase-carrying reporter virus (Koutsoudakis et al. 2006). Time-of-addition experiments revealed that compounds 1 and 2 inhibit HCV virus at a time-point during entry. Furthermore, compounds 1 and 2, apart from cell-free infection inhibited HCV cell-cell transmission. Finally, the results showed that
- Drug Discovery and Drug Development, Healthcare pharmacy, Clinical Studies, Waste management of industrial pharmacy, Good manufacturing practices
Session Introduction
William Jesse
Cleveland Clinic, Abu Dhabi
Title: Improving care across the pharmacy spectrum: Impacting all levels of pharmaceutical excellence through self improvement
Time : 15:50-16:15
Biography:
William Jesse is a Senior Pharmacist in the Ambulatory Pharmacy at Cleveland Clinic, Abu Dhabi, and part of a team of pharmacists, technicians and distribution agents who work tirelessly to provide excellent pharmaceutical care for the patients of Cleveland Clinic Abu Dhabi. Together the Ambulatory Pharmacy team at Cleveland Clinic Abu Dhabi strives to improve the patient experience as our patients transition from clinical care in the doctor’s office to their homes with comprehensive services in counseling, allergy and drug interaction monitoring, and striving to minimize poly-pharmacy as much as possible.
Abstract:
Improving the care provided at different levels of the pharmaceutical spectrum is a difficult task. The only way to affect real change in the current business environment is to dramatically alter your approach towards excellence on a personal and professional level. This workshop-like presentation will introduce you to new concepts and ideas for taking steps to improve the landscape of your business. Industry, community, hospital or sales, the only way to make your work better is to understand the why and the how of what you do. Throughout this presentation, the audience will be immersed in a learn-practice-learn session seeking to enhance the take-away knowledge to be applied in the daily work life. We will look at different leadership styles, and thoughts and how they apply to pharmacy and to healthcare. We will also then examine our approach to improving customer service, whether the customer is a patient, physician, stakeholder, research team, classroom or coworkers
Hisham H A Mohammedkhair
University of Khartoum, Sudan
Title: The role of introducing new applicable method and procedure in good laboratory practice (GLP) leading to good manufacturing process (GMP)
Time : 16:15-16:40
Biography:
Hisham H A Mohammedkhair has completed his Bachelor’s degree at University of Khartoum in Sudan and graduate study of qualifying year at the Institute of the Endemic Disease - University of Khartoum. He is a laboratory manager of Almujlad Hospital attending several workshops in medical laboratory; with experience of seven years and is the member of Sudanese Inventors Union.
Abstract:
The GLP is not satisfied without methods and procedures minimizing errors and maximizing accuracy and precision. So GLP is an essential part of GMP. Here according to this article I want to explain the problems of method used in clinical laboratory and analytical chemistry when constructing calibration STD Graphs (the equation of dilution)when preparing number of points run in arithmetic progression; which include increasing error possibility and shortage of stock STD and the avoidance of these errors by introducing new method APW arithmetic progression way in calibration STD curves or Hisham’s method in calibration STD Graphs which depends on the available volume; When preparing plenty number of points run in arithmetic progression manner. Furthermore it can be used to modify sensitive device to suck solution in arithmetic progression manner depending on difference and the available volume (A.P.W sucking devices).
Israa H Al-Ani
Al-Ahliyya Amman University, Jordan
Title: Formulation of levofloxacin as orodispersible tablets using readymade excipients blend in comparison to classic formulation strategies
Time : 16:40-17:05
Biography:
Israa H Al-Ani has completed her PhD in 2007 from University of Baghdad in Pharmaceutical Sciences. Now she is working as an Assistant Professor of Pharmaceutics in Faculty of Pharmacy and Medical Science, Al-Ahliyya Amman University in Jordan. She has published papers in reputed journals both in pharmaceutical technology and drug delivery systems, and has been serving as a Reviewer for reputated Journals like "Pharmaceutical Research" and "African Journal of Pharmacy and Pharmaceutical Sciences". She has supervised Master degree students. She is a member of "The three-circles of Alemat Project" sponsered by the " Jordan Society for Scientific Research (JSSR) and USAID.
Abstract:
Readymade excipients blends are gaining wide attention in pharmaceutical industry these days especially for tablet production. An orodispersible tablet is intended to be placed in the mouth where it disperses rapidly before swallowing. The aim of this study is to compare the readymade exciepient blend designed for orodispersible tablets with the conventional method to manufacture them using levofloxacin as the active pharmaceutical ingredients. Different formulas were prepared to compare the powder characteristics and then were compressed using direct compression method. The compressed tablets were then evaluated for their physical characteristics and drug release properties. Results showed that using the readymade blend was advantageous regarding powder and tablets physical properties as well as drug release and dissolution.